2.250.000 people have already made a change
Day echoes the importance of replenishing what your body loses during weight reduction
The separate TRANSCEND-T2D Phase 3 program covers type 2 diabetes (TRANSCEND-T2D-1 reported topline results March 19, 2026)
In addition to the covariates included in the GWAS, we also included years of education as a proxy for socio-economic status, and binary indicators of previous disease diagnosis for T2D, hypertension and non-alcoholic fatty liver disease
The author holds equity interest in RNA Therapeutics Inc, DEI Biopharma Inc, Abyolo, and BioRx Inc, but none of these create any conflict of interest for this paper
In orforglipron's study, up to 10% of patients stopped treatment, compared with 3% on placebo